Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
基本信息
- 批准号:10737872
- 负责人:
- 金额:$ 7.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AfricaAgeAnimal ModelAntibodiesAntibody-mediated protectionB-LymphocytesBindingBody FluidsCallithrix jacchus jacchusCell surfaceCellsChildCollaborationsComplexDataDetectionDevelopmentDiseaseEndothelial CellsEndotheliumEpithelial CellsEpitheliumFibroblastsFutureGlycoproteinsGoalsHIV/AIDSHerpesviridaeHerpesviridae InfectionsHumanHuman Herpesvirus 8Human bodyIatrogenesisImmunityImmunizeImmunocompetentImmunocompromised HostImmunologic Deficiency SyndromesImmunosuppressionIn VitroInfectionKaposi SarcomaLaboratoriesLesionLymphocyteMalignant NeoplasmsMalignant lymphoid neoplasmMaternal antibodyMeasuresMembraneModelingMonoclonal AntibodiesOralOral cavityPatternPersonsPredispositionPreventive vaccinePrimary InfectionPrimatesReceptor CellRecombinantsReportingResearchRiskRoleSalivaSamplingSexually Transmitted DiseasesSignal TransductionSiteT-LymphocyteTestingTonsilTransplant RecipientsTropismViralViremiaVirionVirus DiseasesWisconsinWorkcell typedesignexperimental studyhuman modelimmunosuppressedin vivoin vivo Modellatent infectionmutantnonhuman primatenoveloral infectionpermissivenesspolyclonal antibodypolyclonal human antibodypreventprophylacticreceptorskin lesionsuccesstooltransmission processvaccine candidatevaccine development
项目摘要
PROJECT SUMMARY
More than 44,000 new cases of Kaposi sarcoma (KS) are reported globally each year, 84% of which occur in
Africa. This and other Kaposi sarcoma-associated herpesvirus (KSHV)-induced malignancies predominate in
people with acquired or iatrogenic immunodeficiencies. Although KSHV can be detected in other human body
fluids, its frequent detection in saliva in groups both with and without risk of sexually transmitted infections (e.g.,
children) suggests that the oral cavity is the site of primary acquisition. However, the mechanism of KSHV oral
transmission in vivo, particularly the critical viral envelope glycoproteins (gps) required for viral entry,
remains unresolved. Several KSHV–host interactions have been identified, but all prior experiments were
performed in vitro and have not been validated in vivo due to prior lack of an appropriate animal model. Through
collaboration with the Wisconsin National Primate Research Center, our laboratory has access to the common
marmoset (Callithrix jacchus, CJ), a recently developed KSHV non-human primate model that is susceptible to
KSHV oral infection, and under immunosuppression acquires KS-like skin lesions. The objective of this
application is to elucidate the minimum gps required to initiate primary oral infection in vivo, as a prerequisite to
selecting key gps for developing an effective prophylactic vaccine candidate. This application builds on Dr.
Ogembo’s recently completed NCI K01 CA184388-05 research on KSHV entry mechanisms and vaccine
development. Recently, we showed that in vitro, the KSHV glycoprotein gH/gL is essential for viral infection of
epithelial, endothelial, and fibroblasts cells, but not B cells. Notably, we and others have also shown that both
monoclonal and polyclonal Abs to KSHV glycoproteins gB, gH/gL, and gpK8.1, can neutralize KSHV infection of
diverse permissive human cells in vitro. Building on this success, we generated KSHV deletion mutants lacking
the four glycoproteins thought to be critical for viral entry (gB, gH/gL, gpK8.1) and various monoclonal antibodies
specific to these gps. In this project, we will use human ex vivo samples and the CJ KSHV model to test the
hypothesis that gB and gH/gL are critical for KSHV in vivo oral transmission. The premise of our proposal is
built on strong evidence that 1) KSHV can infect CJ, which develop KS-like skin lesions, and 2) Abs against the
KSHV glycoproteins gB and gH/gL can neutralize KSHV infection in vitro and ex vivo. Furthermore, the
permissiveness to KSHV infection of human cells ex vivo and CJ makes these platforms ideal to test the KSHV
gp requirements for infection. Successful completion of the proposed study will elucidate the minimum KSHV
gps required for primary infection in ex vivo and in vivo models, advancing our long-term goal of defining the
initial steps in KSHV infection of humans and the role of antibodies in protecting against the early steps of KSHV
transmission. This will ultimately inform design and development of prophylactic vaccines that can prevent KSHV
infection and its associated cancers.
项目总结
全球每年报告的卡波西肉瘤(KS)新病例超过44,000例,其中84%发生在
非洲。这种和其他卡波西肉瘤相关疱疹病毒(KSHV)诱导的恶性肿瘤在
有获得性或医源性免疫缺陷的人。虽然在其他人体内也能检测到KSHV
体液,在有和无性传播感染风险的人群中唾液中频繁检测到它(例如,
儿童)表明口腔是初级习得的部位。然而,KSHV口服的作用机制
体内传播,特别是病毒进入所需的关键病毒包膜糖蛋白(GPS);
仍然悬而未决。已经确定了几种KSHV与宿主的相互作用,但所有先前的实验都是
在体外进行,由于之前缺乏合适的动物模型,尚未在体内得到验证。穿过
与威斯康星州国家灵长类研究中心合作,我们的实验室可以访问公共
绒猴(Callithrix Jacchus,CJ),一种新开发的KSHV非人类灵长类动物模型,易患
KSHV口腔感染,并在免疫抑制下获得KS样皮肤病变。这样做的目的是
应用是阐明在活体内启动原发口腔感染所需的最低GPS,作为
选择关键GPS以开发有效的预防疫苗候选。此应用程序构建在DR的基础上。
Ogebo最近完成的KSHV进入机制和疫苗的NCI K01 CA184388-05研究
发展。最近,我们在体外证明了KSHV糖蛋白Gh/gl在病毒感染过程中是必不可少的。
上皮细胞、内皮细胞和成纤维细胞,但不是B细胞。值得注意的是,我们和其他人还表明,
抗KSHV糖蛋白gB、Gh/gl和gpK8.1的单抗和多克隆抗体可中和KSHV感染
体外培养的人类细胞种类繁多。在这一成功的基础上,我们产生了KSHV缺失突变体
被认为对病毒进入至关重要的四种糖蛋白(gb、Gh/gl、gpK8.1)和各种单抗
特定于这些GPS。在这个项目中,我们将使用人体体外样本和CJ KSHV模型来测试
假设Gb和Gh/gl是KSHV在体内口服传播的关键。我们提议的前提是
基于强有力的证据:1)KSHV可以感染CJ,导致KS样皮肤病变;2)抗KSHV抗体
KSHV糖蛋白gB和Gh/gl在体外和体外均能中和KSHV感染。此外,
体外细胞和CJ对KSHV感染的通透性使这些平台成为检测KSHV的理想平台
全科医生对感染的要求。成功完成拟议的研究将阐明最低的KSHV
在体外和体内模型中初次感染所需的GPS,推进了我们定义
人类感染KSHV的最初步骤和抗体在预防早期感染KSHV中的作用
变速箱。这最终将为预防KSHV的预防性疫苗的设计和开发提供信息
感染及其相关癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Javier Gordon Ogembo其他文献
Correction: HPV genotyping by L1 amplicon sequencing of archived invasive cervical cancer samples: a pilot study
- DOI:
10.1186/s13027-024-00589-0 - 发表时间:
2024-06-19 - 期刊:
- 影响因子:2.800
- 作者:
Charles D. Warden;Preetam Cholli;Hanjun Qin;Chao Guo;Yafan Wang;Chetan Kancharla;Angelique M. Russell;Sylvana Salvatierra;Lorraine Z. Mutsvunguma;Kerin K. Higa;Xiwei Wu;Sharon Wilczynski;Raju Pillai;Javier Gordon Ogembo - 通讯作者:
Javier Gordon Ogembo
Javier Gordon Ogembo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Javier Gordon Ogembo', 18)}}的其他基金
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10623087 - 财政年份:2021
- 资助金额:
$ 7.4万 - 项目类别:
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection
KSHV 亚单位候选疫苗可引发针对 KSHV 感染的有效体液免疫反应
- 批准号:
10376277 - 财政年份:2021
- 资助金额:
$ 7.4万 - 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10474478 - 财政年份:2021
- 资助金额:
$ 7.4万 - 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10318876 - 财政年份:2021
- 资助金额:
$ 7.4万 - 项目类别:
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection
KSHV 亚单位候选疫苗可引发针对 KSHV 感染的有效体液免疫反应
- 批准号:
10559659 - 财政年份:2021
- 资助金额:
$ 7.4万 - 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10627167 - 财政年份:2021
- 资助金额:
$ 7.4万 - 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10599690 - 财政年份:2021
- 资助金额:
$ 7.4万 - 项目类别:
A multivalent prophylactic and therapeutic vaccine against EBV infection and EBV-associated malignancies
针对 EBV 感染和 EBV 相关恶性肿瘤的多价预防性和治疗性疫苗
- 批准号:
10247243 - 财政年份:2020
- 资助金额:
$ 7.4万 - 项目类别:
Characterization of Epstein-Barr virus monoclonal antibodies as tools for diagnosing and prevention of EBV infection in transplant settings
EB 病毒单克隆抗体作为移植环境中诊断和预防 EBV 感染工具的表征
- 批准号:
9797160 - 财政年份:2018
- 资助金额:
$ 7.4万 - 项目类别:
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
一种预防 EBV 感染和 EBV 相关恶性肿瘤的新型 VLP 疫苗
- 批准号:
9302981 - 财政年份:2017
- 资助金额:
$ 7.4万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Effect of tea flavonoids and low dose estrogen on bone metabolism in an animal model for age-related bone loss
茶黄酮和低剂量雌激素对年龄相关性骨质流失动物模型骨代谢的影响
- 批准号:
488140-2016 - 财政年份:2018
- 资助金额:
$ 7.4万 - 项目类别:
Postdoctoral Fellowships
The Structural and Metabolic Changes Associated with Ependymal Layer Disruption in the Age Continuum of Hydrocephalus - A Human and Animal Model Study
脑积水年龄连续体中与室管膜层破坏相关的结构和代谢变化 - 人类和动物模型研究
- 批准号:
376678 - 财政年份:2017
- 资助金额:
$ 7.4万 - 项目类别:
Studentship Programs
Effect of tea flavonoids and low dose estrogen on bone metabolism in an animal model for age-related bone loss
茶黄酮和低剂量雌激素对年龄相关性骨质流失动物模型骨代谢的影响
- 批准号:
488140-2016 - 财政年份:2017
- 资助金额:
$ 7.4万 - 项目类别:
Postdoctoral Fellowships
Effect of tea flavonoids and low dose estrogen on bone metabolism in an animal model for age-related bone loss
茶黄酮和低剂量雌激素对年龄相关性骨质流失动物模型骨代谢的影响
- 批准号:
488140-2016 - 财政年份:2016
- 资助金额:
$ 7.4万 - 项目类别:
Postdoctoral Fellowships
Animal model of impaired autoregulation for study of age related vascular cognitive impairment
用于研究年龄相关血管认知障碍的自动调节受损动物模型
- 批准号:
9197938 - 财政年份:2016
- 资助金额:
$ 7.4万 - 项目类别:
The domestic cat as an animal model for age-related neurofibrillary tangles
家猫作为年龄相关神经原纤维缠结的动物模型
- 批准号:
24780283 - 财政年份:2012
- 资助金额:
$ 7.4万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Identification of candidate genes responsible for an increased susceptibility of age-related macular degeneration using an animal model and its application to gene diagnosis.
使用动物模型鉴定导致年龄相关性黄斑变性易感性增加的候选基因及其在基因诊断中的应用。
- 批准号:
22591939 - 财政年份:2010
- 资助金额:
$ 7.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
MT1-MMP-based Animal Model of Age-related Macular Degeneration (AMD)
基于 MT1-MMP 的年龄相关性黄斑变性 (AMD) 动物模型
- 批准号:
7481783 - 财政年份:2008
- 资助金额:
$ 7.4万 - 项目类别:
MT1-MMP-based Animal Model of Age-related Macular Degeneration (AMD)
基于 MT1-MMP 的年龄相关性黄斑变性 (AMD) 动物模型
- 批准号:
8101435 - 财政年份:2008
- 资助金额:
$ 7.4万 - 项目类别:
A novel molecular paradigm of age-related macular degeneration in view of the social trend in nocturnal: An approach using an animal model
鉴于夜间活动的社会趋势,年龄相关性黄斑变性的新分子范式:使用动物模型的方法
- 批准号:
20791248 - 财政年份:2008
- 资助金额:
$ 7.4万 - 项目类别:
Grant-in-Aid for Young Scientists (B)